Top

Published in:

01-06-2009 | Original Article

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

Authors: Jill Kolesar, Wei Huang, Jens Eickhoff, Kristine Hahn, Dona Alberti, Steven Attia, William Schelman, Kyle Holen, Anne Traynor, Percy Ivy, George Wilding

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2009

Abstract

Purpose

The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP.

Methods

Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA).

Results

Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 ± 0.94 SD, vs 0.41 ± 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 ± 1.49 SD, vs 0.29 ± 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman’s rank correlation = 0.30; p = 0.12).

Conclusion

RRM2 gene and protein expression varies by tumor type.

Thelander M, Gräslund A, Thelander L (1985) Subunit M2 of mammalian ribonucleotide reductase. J Biol Chem 260:2737–2741PubMed

Larsson A, Sjöberg BM (1986) Identification of the stable free radical tyrosine residue in ribonucleotide reductase. EMBO J 5:2037–2040PubMed

Elford HL, Freese M, Passamani E, Morris HP (1970) Ribonucleotide reductase and cell proliferation. J Biol Chem 245:5228–5233PubMed

Heidel JD, Liu JY, Yen Y, Zhou B, Heale BS, Rossi JJ, Bartlett DW, Davis ME (2007) Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res 13(7):2207–2215PubMedCrossRef

Avolio TM, Lee Y, Feng N, Xiong K, Jin H, Wang M, Vassilakos A, Wright J, Young A (2007) RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo. Anticancer Drugs 18(4):377–388PubMedCrossRef

Fan H, Villegas C, Huang A, Wright JA (1998) The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res 58:1650–1653 (Bibliographic links)PubMed

Fan H, Villegas C, Wright JA (1996) Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci USA 93:14036–14040PubMedCrossRef

Zhou BS, Tsai P, Ker R, Tsai J, Ho R, Yu J et al (1998) Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 16:43–49PubMedCrossRef

Kuo ML, Hwang HS, Sosnay PR, Kunugi KA, Kinsella TJ (2003) Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity. Cancer J 9:277–285PubMedCrossRef

10.

Huang A, Fan H, Taylor WR, Wright JA (1997) Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability. Cancer Res 57:4876–4881PubMed

11.

Zhou BS, Hsu NY, Pan BC, Doroshow JH, Yen Y (1995) Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. Cancer Res 55:1328–1333PubMed

12.

Goan YG, Zhou B, Hu E, Mi S, Yen Y (1999) Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59:4204–4207PubMed

13.

Jung CP, Motwani MV, Schwartz GK (2001) Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 7:2527–2536PubMed

14.

Schelman WR, Holen K, Mulkerin D, Kolesar J, Thomas J, Kruse M, Oliver K, Marnocha R, Eickhoff J, Wilding G (2006) ASCO Annual Meeting Proceedings part I. vol 24, No. 18S (June 20 Supplement). J Clin Oncol, p 12011

15.

Chang JE, Morgan Meadows S, Traynor A, Kolesar J, Marnocha R, Lee F, Eickoff J, Beth E, Binger K, Wilding G (2006) ASCO Annual Meeting Proceedings part I. Vol 24, No. 18S (June 20 Supplement). J Clin Oncol, p 13168

16.

Attia S, Kolesar J, Mahoney M, Pitot H, Laheru D, Heun J, Huang W, Antholine W, Erlichman C, Holen K (2008) A Phase 2 Consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs (in press)

17.

Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8(11):1323–1327PubMedCrossRef

18.

Rubin MA, Zerkowski MP, Camp RL et al (2004) Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol 164(3):831–840PubMed

19.

Warren M, Twohig M, Pier T, Eickhoff J, Lin CY, Jarrard D, Huang W (2008) Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis. Appl Immunohistochem Mol Morphol (online 19 Sep 2008)

20.

Therasse P, Arbuck SG, Eisenhauer EA (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef

21.

Juhasz A, Vassilakos A, Chew HK, Gandara D, Yen Y (2006) Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. Oncol Rep 15(5):1299–1304PubMed

22.

Knox JJ, Hotte SJ, Kollmannsberger C, Winquist E, Fisher B, Eisenhauer EA (2007) Phase II study of triapine (R) in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). Invest New Drugs 25(5):471–477PubMedCrossRef

23.

Mackenzie MJ, Saltman D, Hirte H, Low J, Johnson C, Pond G, Moore MJ (2007) A phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium. Invest New Drugs 25:553–558PubMedCrossRef

24.

Georgoulias V, Kouroussis C, Agelidou A, Boukovinas I, Palamidas P, Stavrinidis E, Polyzos A, Syrigos K, Veslemes M, Toubis M, Ardavanis A, Tselepatiotis E, Vlachonikolis I (2004) Lung Cancer Committee of the Hellenic Oncology Research Group. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer 91(3):482–488

25.

Bosl GJ, Fair WR, Herr HW, Bajorin DF, Dalbagni G, Sarkis AS, Reuter VE, Cordon-Cardo C, Sheinfeld J, Scher HI (1994) Bladder cancer: advances in biology and treatment. Crit Rev Oncol Hematol 16(1):33–70PubMedCrossRef

Title: Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors
Authors: Jill Kolesar
Wei Huang
Jens Eickhoff
Kristine Hahn
Dona Alberti
Steven Attia
William Schelman
Kyle Holen
Anne Traynor
Percy Ivy
George Wilding
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-008-0845-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?

Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form

To widen the setting of cancer patients who could benefit from metronomic capecitabine

MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents

Do anthocyanins and anthocyanidins, cancer chemopreventive pigments in the diet, merit development as potential drugs?

Anticancer activities of sesquiterpene lactones from Cyathocline purpurea in vitro

Keynote webinar | Spotlight on antibody–drug conjugates in cancer